Talk Bio

FDA disputes Capricor's claims of Phase 3 success for DMD cell therapy, deramiocel

Capricor Shares Plunge After FDA Says DMD Therapy Lacks Efficacy Ahead of Advisory Committee Meeting

Capricor Sues Nippon Shinyaku and NS Pharma Over Pricing Flaw and Launch Delays for Deramiocel DMD Therapy

Capricor Shares Rise as FDA Sets August 2026 Decision Date for Deramiocel in Duchenne Muscular Dystrophy After Prior Rejection

Capricor Claims FDA Misinterpreted Efficacy Data Leading to Rejection of DMD Therapy

FDA Rejects Capricor's Cell Therapy for Duchenne Muscular Dystrophy